These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 25640395)

  • 1. Evaluation of BCL6 and MUM1 expression in patients with diffuse large B cell lymphoma and their correlations with staging and prognosis in Iran.
    Rahimi H; Jafarian A; Samadi A; Meamar B; Rahmani S
    Asian Pac J Cancer Prev; 2015; 16(1):83-6. PubMed ID: 25640395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD10, BCL6, and MUM1 expression in diffuse large B-cell lymphoma on FNA samples.
    Cozzolino I; Varone V; Picardi M; Baldi C; Memoli D; Ciancia G; Selleri C; De Rosa G; Vetrani A; Zeppa P
    Cancer Cytopathol; 2016 Feb; 124(2):135-43. PubMed ID: 26414904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical Expression of CD10, BCL6 and MUM1 in Differentiating Diffuse Large B Cell Lymphoma Subtypes.
    Bajwa AA; Khadim MT; Din HU; Ali SS; Jamil U; Khan UAS
    J Coll Physicians Surg Pak; 2017 Oct; 27(10):621-624. PubMed ID: 29056123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extranodal involvement of diffuse large B-cell lymphoma in the head and neck: An indicator of good prognosis.
    Lee DY; Kang K; Jung H; Park YM; Cho JG; Baek SK; Kwon SY; Jung KY; Woo JS
    Auris Nasus Larynx; 2019 Feb; 46(1):114-121. PubMed ID: 29861074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma.
    De Mello CA; De Andrade VP; De Lima VC; Carvalho AL; Soares FA
    Leuk Lymphoma; 2011 Aug; 52(8):1495-503. PubMed ID: 21623692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic markers and gene abnormalities in subgroups of diffuse large B-cell lymphoma: single center experience.
    Korać P; Dominis M
    Croat Med J; 2008 Oct; 49(5):618-24. PubMed ID: 18925695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunophenotyping and molecular genetic analysis of diffuse large B-cell lymphoma].
    Han YS; Xue YQ; Yang HY; Zhang J; Pan JL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):143-7. PubMed ID: 23568722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New prognostic relevant factors in primary cutaneous diffuse large B-cell lymphomas.
    Hallermann C; Niermann C; Fischer RJ; Schulze HJ
    J Am Acad Dermatol; 2007 Apr; 56(4):588-97. PubMed ID: 17289214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.
    van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM
    J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of de novo diffuse large B-cell lymphoma with a translocation of c-myc and immunoglobulin genes.
    Kikuchi A; Nakamura N; Kuze T; Sasaki Y; Abe M; Ohno H; Akasaka T; Nakamura S; Ohshima K; Ando K
    Leuk Res; 2008 Aug; 32(8):1176-82. PubMed ID: 18460403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
    Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
    Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-immunoglobulin/BCL6 gene fusion in diffuse large B-cell lymphoma: prognostic implications.
    Ueda C; Akasaka T; Ohno H
    Leuk Lymphoma; 2002 Jul; 43(7):1375-81. PubMed ID: 12389616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
    Jerkeman M; Aman P; Cavallin-Stahl E; Torlakovic E; Akerman M; Mitelman F; Fioretos T
    Int J Oncol; 2002 Jan; 20(1):161-5. PubMed ID: 11743658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis.
    Bodoor K; Matalka I; Hayajneh R; Haddad Y; Gharaibeh W
    Asian Pac J Cancer Prev; 2012; 13(7):3037-46. PubMed ID: 22994707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
    Seki R; Ohshima K; Fujisaki T; Uike N; Kawano F; Gondo H; Makino S; Eto T; Moriuchi Y; Taguchi F; Kamimura T; Tsuda H; Ogawa R; Shimoda K; Yamashita K; Suzuki K; Suzushima H; Tsukazaki K; Higuchi M; Utsunomiya A; Iwahashi M; Imamura Y; Tamura K; Suzumiya J; Yoshida M; Abe Y; Matsumoto T; Okamura T
    Cancer Sci; 2009 Oct; 100(10):1842-7. PubMed ID: 19656156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N; Uner A; Benekli M; Barista I
    Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin D1-positive diffuse large B-cell lymphoma with IGH-CCND1 translocation and BCL6 rearrangement: a report of two cases.
    Al-Kawaaz M; Mathew S; Liu Y; Gomez ML; Chaviano F; Knowles DM; Orazi A; Tam W
    Am J Clin Pathol; 2015 Feb; 143(2):288-99. PubMed ID: 25596256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Round-robin test for the cell-of-origin classification of diffuse large B-cell lymphoma-a feasibility study using full slide staining.
    Reinke S; Richter J; Fend F; Feller A; Hansmann ML; Hüttl K; Oschlies I; Ott G; Möller P; Rosenwald A; Stein H; Altenbuchinger M; Spang R; Klapper W
    Virchows Arch; 2018 Sep; 473(3):341-349. PubMed ID: 29730836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.